CSPC Pharmaceutical Group Limited
CSPCY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,829,618 | $14,591,337 | $16,276,552 | $7,585,033 |
| % Growth | -87.5% | -10.4% | 114.6% | – |
| Cost of Goods Sold | $628,998 | $4,641,094 | $4,627,537 | $7,893,917 |
| Gross Profit | $1,200,620 | $9,950,243 | $11,649,015 | $18,678,314 |
| % Margin | 65.6% | 68.2% | 71.6% | 246.3% |
| R&D Expenses | $2,939,537 | $2,982,439 | $2,540,784 | $1,152,426 |
| G&A Expenses | $440,186 | $468,768 | $680,006 | $719,497 |
| SG&A Expenses | $3,781,352 | $4,552,613 | $5,813,464 | $5,382,158 |
| Sales & Mktg Exp. | $3,341,167 | $4,133,803 | $5,083,501 | $4,662,660 |
| Other Operating Expenses | $0 | -$11,043 | $11,044 | -$2,939,637 |
| Operating Expenses | $6,720,889 | $7,524,009 | $8,365,292 | $3,594,947 |
| Operating Income | $354,109 | $2,009,410 | $3,700,547 | $1,789,639 |
| % Margin | 19.4% | 13.8% | 22.7% | 23.6% |
| Other Income/Exp. Net | $75,632 | $127,421 | $98,779 | -$10,026 |
| Pre-Tax Income | $429,742 | $2,136,831 | $3,799,326 | $1,779,613 |
| Tax Expense | $595,677 | $570,034 | $749,308 | $1,005,026 |
| Net Income | $351,198 | $1,586,394 | $3,018,940 | $1,378,684 |
| % Margin | 19.2% | 10.9% | 18.5% | 18.2% |
| EPS | 0.12 | 0.48 | 1.08 | 1.44 |
| % Growth | -75% | -55.6% | -25% | – |
| EPS Diluted | 0.12 | 0.48 | 1.08 | 1.44 |
| Weighted Avg Shares Out | 2,858,206 | 2,934,667 | 2,960,002 | 2,962,730 |
| Weighted Avg Shares Out Dil | 2,858,232 | 2,934,511 | 2,959,674 | 2,963,111 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13,060 | $116,851 | $0 | $0 |
| Interest Expense | $2,985 | $0 | $0 | $9,019 |
| Depreciation & Amortization | $657,168 | $766,168 | $549,702 | $0 |
| EBITDA | $3,480,614 | $2,497,898 | $4,524,819 | $1,788,632 |
| % Margin | 190.2% | 17.1% | 27.8% | 23.6% |